ICCC - IMMUCELL CORP /DE/
6.52
-0.010 -0.153%
Share volume: 9,481
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.05%
PREVIOUS CLOSE
CHG
CHG%
$6.53
-0.01
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-14-2024 | 08-13-2024 | 11-13-2024 | 03-28-2025 | 05-14-2025 | 08-14-2025 | 11-13-2025 | |
| Assets | ||||||||
| Total Assets | 43.051 M | 41.855 M | 44.449 M | 45.100 M | 45.622 M | 46.721 M | 45.730 M | |
| Current Assets | 11.348 M | 10.794 M | 13.887 M | 15.043 M | 15.920 M | 17.136 M | 16.825 M | |
| Inventories | 7.150 M | 7.300 M | 7.460 M | 7.113 M | 7.357 M | 8.294 M | 9.802 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 960.347 K | 1.324 M | 3.809 M | 3.758 M | 4.599 M | 5.998 M | 3.886 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 26.982 M | 26.397 M | 25.820 M | 25.349 M | 25.019 M | 24.883 M | 24.341 M | |
| Other Assets | 4.721 M | 4.664 M | 4.741 M | 4.709 M | 4.683 M | 4.702 M | 4.564 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 43.051 M | 41.855 M | 44.449 M | 45.100 M | 45.622 M | 46.721 M | 45.730 M | |
| Total liabilities | 18.415 M | 18.400 M | 18.037 M | 17.582 M | 16.628 M | 16.853 M | 15.929 M | |
| Total current liabilities | 4.184 M | 4.557 M | 4.466 M | 4.412 M | 3.866 M | 4.446 M | 3.998 M | |
| Accounts Payable | 2.143 M | 2.563 M | 2.505 M | 2.483 M | 1.969 M | 2.588 M | 2.324 M | |
| Other liabilities | 4.062 M | 4.045 M | 4.148 M | 4.129 M | 4.109 M | 4.144 M | 4.033 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 10.169 M | 9.798 M | 9.423 M | 9.041 M | 8.653 M | 8.263 M | 7.899 M | |
| Other liabilities | 4.062 M | 4.045 M | 4.148 M | 4.129 M | 4.109 M | 4.144 M | 4.033 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 24.636 M | 23.455 M | 26.412 M | 27.518 M | 28.994 M | 29.867 M | 29.801 M | |
| Common stock | 37.220 M | 37.571 M | 41.228 M | 41.820 M | 41.849 M | 42.213 M | 42.286 M | |
| Retained earnings | -12.445 M | -13.977 M | -14.678 M | -14.164 M | -12.717 M | -12.215 M | -12.355 M |